| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | Alkermes plc | Jul 30, 2026 | |
| Sell | ASTELLAS PHARMA INC ADR UNSO | Jul 10, 2018 | |
| Buy | ASTELLAS PHARMA INC ADR UNSO | Jun 1, 2018 | |
| Sell | ASTELLAS PHARMA INC ADR UNSO | Jul 31, 2017 |
This page tracks congressional stock trading activity in Alkermes plc (ALKS) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving ALKS. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of September 2026 — Disclosed Capitol has tracked 4 disclosed congressional trades in Alkermes plc (ALKS) — 2:1 sell-heavy ratio — led by Phil Roe (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jul 30, 2026 | Gilbert Cisneros | D | Buy | $15,001 - $50,000 |
| Jul 10, 2018 | Phil Roe | R | Sale | $1,001 - $15,000 |
| Jun 1, 2018 | Phil Roe | R | Purchase | $1,001 - $15,000 |
| Jul 31, 2017 | Phil Roe | R | Sale | $1,001 - $15,000 |
Across the 4 disclosed congressional trades in Alkermes plc (ALKS), members of Congress have reported 1 buy and 2 sells. The average 30-day alpha vs. the S&P 500 is -7.04%.
For fiscal year 2025, Alkermes plc reported revenue of $1.66B and net income of $355.8M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $888.9M, net income -$66.0M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.